Frequent Loss of Genome Gap Region in 4p16.3 Subtelomere in Early-Onset Type 2 Diabetes Mellitus by Kudo, Hirohito et al.
Hindawi Publishing Corporation
ExperimentalDiabetes Research
Volume 2011, Article ID 498460, 10 pages
doi:10.1155/2011/498460
Research Article
Frequent LossofGenome GapRegi o ni n4p 16.3S u bt e l o m e r ei n
Early-Onset Type 2 Diabetes Mellitus
Hirohito Kudo,1 Mitsuru Emi,2 YasushiIshigaki,1 Uiko Tsunoda,1 YoshinoriHinokio,1
Miho Ishii,2 HidenoriSato,2 Tetsuya Yamada,3 Hideki Katagiri,3 and Yoshitomo Oka1
1Division of Molecular Metabolism and Diabetes, TohokuUniversity Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku,
Sendai, Miyagi 980-8575, Japan
2CNV Laboratory, DNA Chip Research Institute, 1-1-43 Suehiro-cho, Tsurumi-ku Yokohama, Kanagawa 230-0045, Japan
3Department of Metabolic Diseases, Center for Metabolic Diseases, Tohoku University Graduate School of Medicine,
2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan
Correspondence should be addressed to Hideki Katagiri, katagiri@med.tohoku.ac.jp
Received 6 October 2010; Revised 21 February 2011; Accepted 30 March 2011
Academic Editor: Kazuya Yamagata
Copyright © 2011 Hirohito Kudo et al.Thisisanopen accessarticledistributed undertheCreative CommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A small portion of Type 2 diabetes mellitus (T2DM) is familial, but the majority occurs as sporadic disease. Although causative
genes are found in some rare forms, the genetic basis for sporadic T2DM is largely unknown. We searched for a copy number
abnormality in 100 early-onset Japanese T2DM patients (onset age <35 years) by whole-genome screening with a copy number
variationBeadChip. Within the 1.3-Mb subtelomeric region on chromosome4p16.3, we found copy number losses in early-onset
T2DM (13 of 100 T2DM versus one of 100 controls). This region surrounds a genome gap, which is rich in multiple low copy
repeats. Subsequent region-targeted high-densitycustom-madeoligonucleotidemicroarrayexperiments veriﬁed the copy number
losses and delineated structural changes in the 1.3-Mb region. The results suggested that copy number losses of the genes in the
deleted region around the genome gap in 4p16.3 may play signiﬁcant roles in the etiology of T2DM.
1.Introduction
T y p e2d i a b e t e sm e l l i t u s( T 2 D M )i sac o m m o nm e t a b o l i c
disease, aﬀecting nearly 300 million individuals worldwide.
T2DM aﬀects over 10% of adult individuals over 40 years
of age in Japan. The continuous increase in the number of
patients is a major public health problem worldwide. Loci
forrare monogenicformsofdiabetes, suchasmaturity-onset
diabetes of the young [1], mitochondrial diabetes [2, 3], and
Wolfram syndrome [4], have been elucidated in a limited
proportion of patients. However, the etiology of sporadic
T2DM remains largely unknown. Accumulating epidemio-
logical evidence [5–8] suggests that genetic factors play an
important role in the susceptibility to sporadic T2DM, in
addition to environmental factors such as obesity, aging, and
exercise.
To search for susceptibility gene(s) for sporadic T2DM,
genome-wide association studies (GWASs) using single nu-
cleotide polymorphism (SNP) markers have been per-
formed. These GWASs and replication studies have found
multiple loci, TCF7L2 [9], KCNQ1 [10, 11], and others
[12–18], that are associated with susceptibility to T2DM.
However, the overall contribution of these SNPs to sporadic
T2DM is relatively low; their odds ratio being in the range
of 1.1–1.4 [9, 11]. In addition, these associations have not
necessarily been replicated in subsequent studies [12–18].
Copynumbervariations(CNVs)orstructuralvariations,
such as deletion or gain of a genomic region, are increas-
ingly recognized as important interindividual genetic vari-
ations across the human genome. CNVs account for more
nucleotide variation between two individuals than do SNPs
[19–21]. Repetitive, multicopy regions, such as segmental
duplications and low copy repeats associated with CNV,
are regarded as “rearrangement hotspots,” and CNV regions
are predisposed to the generation of deletion/duplication
events [22]. Such repeat-rich regions were recently found to2 Experimental Diabetes Research
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Figure 1: Genomic region harboring copy number loss of 1.3-Mb 4p16.3 subtelomeric region in 13 early-onset T2DM patients. Data
measured by deCODE/Illumina CNV370K chip were analyzed by the PennCNV program. Genome structure of the 13 patients are
aligned as horizontal bars from genome position 550,000 (left) to position 1,850,000 (right). Hatched region at position 1,423,147–
1,478,646 represents genome gap-177 region. Dark solid horizontal bars represent extent of copy number loss in each T2DM patient.
Gray regions between the dark bars represent intervals where copy number loss could not be inferred due to poor probe coverage. Upper
map shows ideogram of chromosome 4 and the positions of putative genes in 4p16.3 region described in Database of Genomic Variants
(http://projects.tcag.ca/variation/). Position is given relative to NCBI Build 35 for the chromosome 4.Experimental Diabetes Research 3
show 13-fold enrichment of CNVs over the average genomic
coverage in a reference assembly [23]. Therefore, CNVs or
structural variations are recognized as signiﬁcant contribu-
tors to human genetic disease and disease susceptibility [24].
In the search for susceptibility gene(s) for T2DM genes,
we recruited a panel of 100 early-onset Japanese T2DM
patients (onset age <35 years) and 100 controls, and per-
formed CNV analysis in the whole genome using the
deCODE-Illumina CNV370K BeadChip which focuses on
theCNV-rich region ofthehuman genome,followed by vali-
dation and characterization using an Agilent region-targeted
high-density custom-made oligonucleotide tiling microar-
ray. We found frequent copy number losses within the 1.3-
Mb subtelomeric region in a substantial portion of early-
onsetJapanese T2DMpatients.Thisregionsurroundsthege-
nome gap in 4p16.3, which is rich in multiple low copy
repeats.
2.Materialsand Methods
2.1. Subjects. We considered that the early onset of T2DM
reﬂects the presence of more genetic factors rather than
environmental factors. Therefore, we adopted young-onset
diabetic patients as case subjects. We studied 100 unrelated
Japanese T2DM patients who developed T2DM before
35 years of age. They were recruited at Tohoku Univer-
sity Hospital and aﬃliated hospitals and medical clinics.
Diabetes was diagnosed using the WHO criteria. Type 1
diabetes mellitus was excluded judged from clinical features
and existence of anti-GAD (glutamic acid decarboxylase)
antibodies or anti-IA-2 (insulinoma-associated antigen-2)
antibodies. Patients with diabetes mellitus due to hepatic
disease, pancreatic disease, other endocrinological disease,
or mitochondrial DNA mutation, or drug-induced diabetes
were excluded, judged from laboratory data and clinical
history.
We also studied 100 nondiabetic control subjects, using
the following criteria: 60 or more years of age, no prior
diagnosis of diabetes mellitus, HbA1c less than 6.4% (where
HbA1c (%) was estimated as an NGSP (National Gly-
cohemoglobin Standardization Program) equivalent value
(%) calculated by the formula HbA1c (%) = HbA1c (JDS:
Japan Diabetes Society value) (%) + 0.4%, considering the
relational expression of HbA1c (JDS) (%) measured by
the previous Japanese standard substance and measurement
methods for HbA1c (NGSP) [25] and no family history
of T2DM within third-degree relatives, in order to exclude
subjects who were more likely to develop diabetes later.
Clinical features available from 100 early-onset T2DM
patients and 100 controls are shown in (see Table S1 in
Supplementary Material available online at doi: 10.1155/
2011/498460). In addition, clinical features of the 13 early-
onset T2DM patients with copy number losses in 4p16.3 are
shown separately in Supplementary Table S2 and Supple-
mentary Table S3 in comparison with the rest of 100 early-
onset T2DM patients without copy number loss (n = 87).
Genetic analysis of human subjects was approved by the
ethics committee of Tohoku University Graduate School of
Medicine. Appropriate informed consent was obtained from
all the subjects examined.
2.2. Screening with Whole-Genome CNV BeadChip. We
screened the whole genome by CNV analysis using the
deCODE-Illumina CNV370K BeadChip (Illumina Inﬁnium
system, deCODE genetics, Inc., Iceland), which, in addition
to Hap300 SNP marker contents, has CNV probes designed
to target the CNV-rich region of the whole genome. The
CNV part of the platform consists of probes covering CNV-
rich regions of the genome, such as megasatellites (tan-
dem repeats >500bp), duplicons (region ﬂanked by highly
homologous segmental duplication >1kb), unSNPable re-
gions (>15kb gaps in HapMap SNP map, and 5–15kb gaps
with >2SNPs with Hardy-Weinberg failure), and CNVs reg-
istered in the Database of Genomic Variants. The CNV part
of probe content consists of 15,559 CNV segments covering
190Mb,or6%ofthehuman genome.The platformhas been
tested in 4000 Icelandic and HapMap samples.
Data analysis of the deCODE-Illumina CNV chip was
carried out using DosageMiner software developed by
deCODE genetics, and loss/gain analysis consisted of the fol-
lowing four steps; (1) intensity normalization and GC con-
tent correction, (2) removal of batch eﬀects using principal
component analysis, (3) calling of clusters using a Gaussian
mixture model, and (4) determination of CNV type using
graphical constraints. In brief, CNVs were identiﬁed when
CNV events stood out in the data, as all sample intensities
for CNV probes should be increased or decreased relative
to neighboring probes that are not in a CNV region.
To determine deviations in signal intensity we started by
normalizing the intensities. The normalized intensities for
each color channel were determined by an equation and
ﬁt formula developed by deCODE genetics. A stretch with
occurrence of more than one marker showing abnormality
in the copy number in a consecutive stretch in the genome
is considered more likely to be evidence of deletion or gain
[26]. We display Supplementary Table to present raw data,
thatis,log2 ratiomeasuredateachprobeforeveryindividual.
Raw data at screening step via deCODE/Illumina beads chip
forall probesonchromosome 4pisshown inSupplementary
Table S4.
2.3. High-Density Custom-Made Oligonucleotide Tiling Mi-
croarray Analysis. DNA samples from 13 early-onset T2DM
patients and 15 control individuals were subjected to Agi-
lent’s high-density custom-made oligonucleotide tiling mi-
croarray analysis based on an array comparative genomic
hybridization (aCGH) assay. We fabricated a custom-de-
signed microarray targeted to a 1.3-Mb genome region in
the subtelomere at 4p16.3 (Chr. 4: 550,000-1,850,000
(NCBI Build 36.1, hg18)) according to previously described
methods [27, 28]. In brief, we used the Agilent website
(http://earray.chem.agilent.com/earray/) to select and design
our customtiling array; the array consisted of probes60-mer
in size (Agilent Technologies, Santa Clara, CA).
Tiling-aCGH experiments were performed essentially
as described previously [29]. In brief, test and reference
(NA19000, a Japanese male from HapMap project) genomic4 Experimental Diabetes Research
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Figure 2: Detailed structure of copy number loss of 1.3-Mb 4p16.3 subtelomeric region resolved by high-density tiling microarray. Log2
ratio (y-axis) was plotted using moving average along the genome position (x-axis). Four representative early-onset T2DM patients are
shownas Figures 2(a), 2(b), 2(c),a n d2(d), patient 1,2, 3,and 4,respectively. For comparison,log2 ratio ofthe region oftwo healthy normal
individuals is also displayed as Figures 2(e) and 2(f). Dark line represents copy number plot along the genome. Two light lines indicate
normal range of average log2 ratios for probes among normal individuals. Dotted line shows median of average log2 ratio among normal
individuals. Copy number losses are displayed as gray vertical bar. We deﬁned two copy number classes, that is, “unchanged copy number”
and “copy number loss.” “Unchanged copy number” was deﬁned when the log2 ratio stays within the mean ± 1SD distribution among
the normal population. “Copy number loss” was called when the downward-deviation of log2 ratios exceeded a threshold of 1SD from the
median probe ratio.
DNAs (250ng per sample) were ﬂuorescently labeled with
Cy5 (test) and Cy3 (reference) with a ULS Labeling Kit (Agi-
lent Technologies).
Foreachsample, respectivelabelingreactionsweremixed
and then separated prior to hybridizing to each of the arrays.
Labeled test and reference DNAs were combined, denatured,
preannealed with Cot-1 DNA (Invitrogen) and blocking
agent, and then hybridized to the arrays for 24hr in a ro-
tating oven at 65◦C and 20rpm (Agilent Technologies).
After hybridization and washes, the arrays were scanned at
3µm resolution with an Agilent G2505C scanner. Images
were analyzed with Feature Extraction Software 10.7.3.1
(Agilent Technologies), with the CGH 107 Sep09 protocol
for background subtraction and normalization. DetectionExperimental Diabetes Research 5
Gap (chromosome)
NKX1 -1 NKX1 -1
RefSeq Genes (Gene)
PDE6B|NM_000283
PDE6B|NM_001145291
PDE6B|NM_001145292
ATP5I|NM_007100
MFSD7|NM_032219
MYL5|NM_002477
PCGF3|NM_006315
CPLX1|NM_006651
GAK|NM_005255
TMEM175|NM_032326
IDUA|NM_000203
DGKQ|NM_001347
SLC26A1|NM_134425
SLC26A1|NM_022042
SLC26A1|NM_213613
FGFRL1|NM_001004356
FGFRL1|NM_001004358
FGFRL1|NM_021923
RNF212|NM_001131034
RNF212|NM_194439
SPON2|NM_001128325
SPON2|NM_012445
LOC100130872-SPON2|NR_033182
LOC100130872|NR_024569
CTBP1|NM_001012614
CTBP1|NM_001328
C4orf42|NM_052861
MAEA|NM_001017405
MAEA|NM_005882
Gap_177
KIAA1530|NM_020894
CPIPAK|NM_175918
FAM53A|NM_001013622
SLBP|NM_006527
TMEM129|NM_001127266
TMEM129|NM_138385
TACC3|NM_006342
FGFR3|NM_000142
FGFR3|NM_001163213
FGFR3|NM_022965
LETM1|NM_012318
6 10 14 18
×105
C
a
s
e
(
N
=
1
3
)
10
5
0
Chromosome 4
Position (bp)
Figure 3: The extent of copy number losses within 1.3-Mb 4p16.3 subtelomeric region in 13 early-onset T2DM patients revealed
by high-density oligonucleotide tiling microarray. Dark horizontal bars represent extent of copy number loss region in each patient
revealed by Agilent custom tiling array. Genome structure of the 13 patients is aligned as horizontal bars from genome position 550,000
(left) to position 1,850,000 (right). Hatched region at position 1,423,147–1,478,646 represents genome gap-177 region. Gray regions
represent proximal ends of stretch where copy number status was not inferred due to presence of multiple low copy repeats. Upper
map shows ideogram of chromosome 4 and the positions of putative genes in 4p16.3 region described in Database of Genomic Variants
(http://projects.tcag.ca/variation/). Position is given relative to NCBI Build 35 for the chromosome 4.6 Experimental Diabetes Research
of abnormal copy number, losses, and gains, in a complex
multicopy variable region by high-density tiling array was
accessed by deviation of probe log2 ratios that exceeded
a threshold of 1SD from the median probe ratio, according
to procedures described previously [29–31]. We deﬁned two
copy number classes, that is, “unchanged copy number” and
“copy number loss.” “Unchanged copy number” was deﬁned
whenthelog2 ratiostayswithinthemean±1SDdistribution
among the normal population. “Copy number loss” was
called when the downward-deviation of log2 ratios exceeded
a threshold of 1SD from the median probe ratio. Raw data,
that is, log2ratio measured at each probe for every individual
obtained by high-density custom-made tilling array analysis
is shown in Supplementary Table S5.
3.Results
In searching for CNVs associated with early-onset T2DM,
we screened the whole genome by CNV analysis using
the deCODE-Illumina CNV370K BeadChip in 100 early-
onset Japanese T2DM patients and 100 controls. We found
four CNVs that fulﬁlled our screening criteria: (1) reliable
CNV (size over 50-Kb, consisting of over 50 consecutive
probes), (2) the association being statistically signiﬁcant by
Fisher’s exact test which was accompanied by Bonferroni’s
correction. Four candidate CNV that fulﬁlled the criteria;
that is, CNV on 4p16.3 (P = 6.75 × 10−3 by Fisher’s exact
test, P<. 05 after Bonferroni’s correction), CNV on 16p13.3
(P = 3.44 × 10
−4 by Fisher’s exact test, P<. 05 after
Bonferroni’s correction), CNV on 16q24.3 (P = 9.65 × 10
−3
by Fisher’s exact test, P<. 05 after Bonferroni’s correction),
and CNV on 19p 13.3 (P = 1.61×10
−4 by Fisher’s exact test,
P<. 05 after Bonferroni’s correction). Of these CNVs listed,
the CNV on 4p16.3 was intriguingly found to be located
right on the genome gap-177 region on 4p subtelomere. At
this candidate CNV on 4p16.3, 13 out of 100 T2DM patients
displayed CN-loss around this CNV marker, compared with
1 out of 100 control samples. Because of its unique overlap
with genome gap structure, we focused on this CNV region
for further analysis.
Figure 1 shows the pattern of alterations in copy number
loss observed among the 100 early-onset Japanese 2DM
patients. Thirteen patients displayed copy number losses
around the gap in the 4p16.3 subtelomere whereas only one
of 100 control samples showed copy number losses in this
region.Theassociation was statisticallysigniﬁcant byFisher’s
e x a c tt e s t( P = 6.75 × 10
−3,O R= 14.7, 95% conﬁdence
interval 3.02–72.3). We observed two copy number classes,
that is, “unchanged copy number” and “copy number loss”
at 1.3-Mb region of chromosome 4p16.3 in our diabetic
or control populations. The latter was found frequently
observed among early-onset T2DM patients at the 4p16.3
subtelomere. The position, length, or pattern of deletion
between one copy number loss in control and 13 copy num-
ber losses in T2DM patients were not apparently distinct,
although the case number is too small to draw meaningful
conclusion.
To verify the CNV BeadChip results, we analyzed copy
number changes along the 1.3-Mb region in the subtelomere
surrounding the genome gap of 4p16.3 using a high-density
custom-made oligonucleotide tiling microarray. We used
peripheral blood DNA of the 13 early-onset T2DM patients,
identiﬁed, and 15 control healthy individuals. Again, we
found frequent copy number losses in regions around the
genomegap inall the13early-onset T2DMpatients,whereas
none of 15 healthy individuals showed copy number losses.
Figure 2 shows detailed structure of copy number losses
in four representative early-onset Japanese T2DM patients
with copy number losses, in the 1.3-Mb region in the
subtelomere (patients 1, 2, 3, 4; in Figures 2(a), 2(b), 2(c),
and 2(d), resp.). Individual copy number plots using moving
average (y-axis) versus distance along the chromosome (x-
axis) are shown. As a comparison, copy number plots
of healthy individuals who did not exhibit copy number
alterations in the region are also shown (Figures 2(e) and
2(f)).
Figure 3 shows genomic copy number losses in all the 13
early-onset T2DM patients. High-density tiling custom-
made microarray showed segmental losses in the subtelom-
eric region of 4p16.3 in all the 13 patients. Genomic copy
number losses in these patients were clustered around a gap
region in the 4p16.3 subtelomeric region.
4.Discussion
Our initial genome-wide screening with deCODE-Illumina
CNV370K BeadChip for association with early-onset T2DM
revealed losses in the subtelomeric region of 4p16.3. Sub-
sequent high-density custom-made oligonucleotide tiling
microarray veriﬁed copy number losses in this region.
It is worthy to note that most patients with copy number
losses were treated with insulin injection. Urine C-peptide
reactivity was not signiﬁcantly diﬀerent between the two
groups, and only few patients underwent glucagon challenge
test, thus, the data are too limited to infer the function of
insulin secretion. We did not observe signiﬁcant diﬀerences
between two groups as to age of onset, body mass index,
postprandial plasma glucose levels, or HbA1c levels. Fasting
immunoreactive insulin levels were examined in 5 patients
with copy number losses and 14 patients without copy
number loss. HOMA-R in the former patients was 6.1 ±
6.8( m e a n± SD) and that in the latter patients was
5.5 ± 6.0( m e a n± SD); these values were not signiﬁcantly
diﬀerent. Incidence of dyslipidemia, hypertension, diabetic
retinopathy, nephropathy, or neuropathy was not diﬀerent
between the two groups (Supplementary Tables S2, S3).
Further investigation of a large panel of patients would be
necessary to clarify any clinical diﬀerences that might be
present between the two groups.
The current map ofCNVinthe human genomereported
in theexisting databases isfar from complete[32].Increasing
numbers of CNVs have recently been identiﬁed around
repetitive sequences such as segmental duplications or low
copy repeats. In fact, these repeat-rich regions were found
to be 13-fold enriched in CNV over the average genomic
coverage in the reference assembly [23]. Probes for conven-
tional genome-wide SNP genotyping platforms are likely to
be underrepresented; that is, only 25% and 40% of CNV areExperimental Diabetes Research 7
Table 1: Putative genes located within 1.3-Mb region in 4p16.3 subtelomere.
Start End Cytogenetic
location Symbol Description Model evidence
609,373 654,571 4p16.3 PDE6B
Phosphodiesterase 6B, cGMP-speciﬁc, rod, beta
(congenital stationary night blindness 3,
autosomaldominant)
Best RefSeq
656,225 658,122 4p16.3 ATP5I ATP synthase, H+ transporting, mitochondrial F0
complex, subunit E Best RefSeq
661,711 665,817 4p16.3 MYL5 Myosin, light chain 5, regulatory Best RefSeq
665,618 672,973 4p16.3 MFSD7 Majorfacilitator superfamily domaincontaining7 mRNA
689,573 754,428 4p16.3 PCGF3 Polycomb group ring ﬁnger 3 Best RefSeq
719,829 721,544 4p16.3 LOC100128084 Hypothetical protein LOC100128084 mRNA
764,588 765,632 4p16.3 LOC100129917 Hypothetical protein LOC100129917 mRNA
768,745 809,945 4p16.3 CPLX1 Complexin 1 mRNA
833,065 916,174 4p16.3 GAK Cyclin G associated kinase mRNA
916,262 942,444 4p16.3 TMEM175 Transmembrane protein 175 Best RefSeq
942,675 957,344 4p16.3 DGKQ Diacylglycerol kinase, theta 110kDa Best RefSeq
962,861 977,224 4p16.3 SLC26A1 Solute carrier family 26 (sulfate transporter),
member 1 Best RefSeq
970,785 988,317 4p16.3 IDUA Iduronidase, alpha-L- mRNA
995,610 1,010,686 4p16.3 FGFRL1 Fibroblast growth factor receptor-like 1 Best RefSeq
1,044,654 1,045,386 4p16.3 LOC100132787 Hypothetical protein LOC100132787 mRNA
1,055,269 1,097,350 4p16.3 RNF212 Ring ﬁnger protein 212 Best RefSeq
1,116,050 1,129,814 4p16.3 LOC100133135 Hypothetical protein LOC100133135 Protein
1,135,541 1,135,957 4p16.3 FLJ35816 FLJ35816 protein Protein
1,149,293 1,149,712 4p16.3 LOC100131106 Hypothetical protein LOC100131106 Protein
1,150,723 1,156,597 4p16.3 SPON2 Spondin 2, extracellular matrix protein Best RefSeq
1,184,431 1,185,198 4p16.3 LOC100130872 Hypothetical protein LOC100130872 mRNA
1,195,228 1,232,908 4p16.3 CTBP1 C-terminal binding protein 1 Best RefSeq
1,234,177 1,236,616 4p16.3 C4orf42 Chromosome4 open reading frame 42 Best RefSeq
1,273,672 1,323,925 4p16.3 MAEA Macrophage erythroblast attacher Best RefSeq
1,331,104 1,371,732 4p16.3 KIAA1530 KIAA1530 mRNA
1,375,340 1,379,782 4p16.3 CRIPAK Cysteine-rich PAK1 inhibitor mRNA
1,380,072 1,392,453 4p16.3 NKX1-1 NK1 homeobox 1 Protein
1,484,196 1,519,086 4p16.3 LOC100133199 Similar to RE32881p mRNA
1,611,605 1,655,516 4p16.3 FAM53A Family with sequence similarity 53, member A Best RefSeq
1,664,325 1,683,828 4p16.3 SLBP Stem-loop (histone) binding protein Best RefSeq
1,687,477 1,692,882 4p16.3 TMEM129 Transmembrane protein 129 Best RefSeq
1,693,062 1,716,696 4p16.3 TACC3 Transforming,acidic coiled-coil containing
protein 3 Best RefSeq
1,765,421 1,780,396 4p16.3 FGFR3 Fibroblast growth factor receptor 3
(achondroplasia,thanatophoric dwarﬁsm) Best RefSeq
1,784,558 1,827,772 4p16.3 LETM1 Leucine zipper-EF-hand containing
transmembrane protein 1 Best RefSeq
coveredbytheHumanHap300andHumanHap550platform,
respectively [23]. These recent ﬁndings may partly explain
why earlier genome-wide association studies for CNVs in the
T2DM population failed to detect CNV loci being strongly
associated with T2DM [20, 21, 33, 34].
We found copy number losses among early-onset
Japanese T2DM patients in a region surrounding a genome
gap (gap-177) in the subtelomere of chromosome 4p16.3.
The physical map of the human genome still contains a sig-
niﬁcantnumberofgenomegaps;over300gapsstillremainin
the human draft genome sequence [35] that are considered
inaccessible by most existing genotyping and sequencing
technologies [36]. These gap regions are estimated to har-
bor ∼1000 genes, which comprise approximately 5% of8 Experimental Diabetes Research
the human genome (∼200Mb). In particular, they are
abundant in subtelomeres and pericentromeric regions of
chromosomes [37, 38]. Some of these gaps are thought to
be susceptiblesites formediating meiotic recombinationand
are also susceptibility sites for break points for deletions
[39, 40].
Many CNVs were recently identiﬁed in repeat-rich re-
gions [41], which are predisposed to the generation of de-
letion/duplication events [22]. It is intriguing to note that
the locus-speciﬁc mutation rates for CNV or structural
rearrangements were estimated tobe between10−6 and 10−4:
two to four orders of magnitude greater than nucleotide-
speciﬁc rates for base substitutions or point mutations [19].
The deleted CNV region found in the present study and
its ﬂanking region contained 34 genes (Table 1). Gene(s) in
this region may predispose to T2DM.
Genes involved in the glucose-induced insulin secretion
cascadeofpancreaticbeta-cellsarelocatedintheregion,such
as ATP5I (ATP synthase, H+ transporting, mitochondrial F0
complex, subunit E) [42, 43], CPLX1 (complexin1) [44, 45],
GAK (cyclin G associated kinase) in association with CDK5
(cyclin-dependent protein kinases 5) [46–50], and CRIPAK
(cysteine-rich PAK1 inhibitor), which is a negative regulator
of PAK1 (p21 protein (Cdc42/Rac-) activated kinase 1) [51,
52].
FGFR3(ﬁbroblastgrowthfactorreceptor3)and FGFRL1
(ﬁbroblast growth factor receptor-like 1) are suggested to be
involved in pancreatic development and diﬀerentiation [53–
56].TACC3(transforming, acidiccoiled-coilcontainingpro-
tein3)may beinvolvedin embryonicdevelopmentincluding
the pancreas [57, 58].
CTBP1 (C-terminal binding protein 1) and MAEA (ma-
crophageerythroblastattacher)haveeﬀectsonadipose tissue
functions [59, 60], which may lead to insulin resistance.
NKX1-1(NK1 homeobox 1) may cause insulin resistance
with a function in the maintenance of energy homeostasis
[61].
Recently, through whole-genome screening of a copy
number variation using a CNV BeadChip and real-time
quantitative polymerase chain reaction (qPCR), Kato et al.
identiﬁed a segmental copy number gain within the 40-kb
region on 10p15.3 subtelomere in patients of sporadic amy-
otrophiclateralsclerosis(SALS)[62].Theydemonstratedthe
copynumbergain in46outof83SALSpatients,ascompared
with 10 out of 99 controls. The copy number gain region
they identiﬁed is rather small (40-kb) and harbored two
genes encoding isopentenyl diphosphate isomerase 1 (IDI1)
and IDI2. Thus, they suggested the copy number gain
in the region of these genes may play a signiﬁcant role
in the pathogenesis of SALS. The present study share a
similar genome abnormality in that we found frequent copy
number alterations in subtelomere region among sporadic
adult-onset disease of unknown cause. The copy number
alterations we identiﬁed here in early-onset T2DM were
copy number losses on diﬀerent chromosome subtelomere
(4p16.3) and the size is rather large (up to 1.3-Mb). In
our case, we suspect that multiple genes in the region may
be involved in diabetes pathogenesis through impairments
caused by copy number losses.
5.Conclusion
These resultssuggestedthat copynumber lossesofthecandi-
date genesin the deletedregion surrounding the genome gap
in 4p16.3 may play signiﬁcant roles in the etiology of T2DM.
Further functional study, as well as investigation of 4p16.3
lossina largepanelofearly-onset T2DMpatientsin diﬀerent
ethnic populations and geographical regions, is warranted.
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